Paul Bisaro, who serves as a director at Myriad Genetics Inc., executed a purchase of the company's common stock on May 14, 2026. The transaction saw Mr. Bisaro acquiring 7,500 shares, with each share purchased at a price of $3.685. This buying activity represented a total investment value of $27,637.
Following this specific acquisition, the record indicates that Mr. Bisaro currently holds a total holding of 97,441 shares of Myriad Genetics common stock. The reported transaction provides an insight into internal director confidence regarding the company's valuation.
The recent activity from directors must be considered alongside the firm's broader financial performance. In its first quarter of 2026, Myriad Genetics disclosed financial results that were mixed in nature. Specifically, the company reported an adjusted earnings per share (EPS) loss totaling $0.09. This figure surpassed the previously forecasted loss estimate of $0.0706.
Furthermore, for the same quarter, revenue reached a level of $200.4 million. This total was slightly below the anticipated revenue projection of $202.39 million. These combined results highlight several operational and financial challenges that the company encountered during the period under review. Despite missing both its earnings per share expectations and its revenue targets, the stock experienced a minor increase in aftermarket trading.
The current market reaction suggests that investors are keenly observing how Myriad Genetics plans to address these identified financial shortfalls in subsequent quarters. Consequently, the company's overall performance trajectory is expected to be closely monitored by analysts and the investment community in the coming months.
Key Points for Investors
The recent data points reveal several key observations regarding Myriad Genetics:
- Director Buying Activity: The purchase of shares by director Paul Bisaro on May 14, 2026, signals an internal transaction.
- Q1 Financial Underperformance: The company reported an adjusted EPS loss of $0.09 and revenue of $200.4 million for Q1 2026.
- Market Reaction to Results: Despite the missed earnings and revenue expectations, the stock saw a minor increase in aftermarket trading.
Potential Risks and Uncertainties
The primary uncertainties surrounding Myriad Genetics are directly linked to its financial performance:
- Future Financial Correction: The company must address the Q1 shortfalls, including missing both revenue and EPS forecasts.
- Sustaining Market Confidence: Investors will be closely monitoring management's plan to stabilize future earnings and revenues following the mixed quarterly results.
Impacted Sectors
The information primarily impacts the biotechnology and healthcare sectors, particularly those focused on genetics and diagnostic services.
This analysis is based solely on publicly reported transactions and financial data provided for Q1 2026.